Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Bajaj Healthcare enters into CDMO contract with UK/EU-based companies for 15 new APIs

Ruchika Sharma10 Dec 2024 11:30 AM IST

Thane: Bajaj Healthcare has informed the exchanges that the Company has entered into a definitive contract development and manufacturing...

Girl With Fever Given Rabies Vaccine, Probe Ordered

USFDA approves commercial production of Vasostrict at Endo newest Indore facility

Ruchika Sharma10 Dec 2024 10:15 AM IST

Malvern: Endo, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved commercial production of VASOSTRICT...

Alembic Pharma commissions new manufacturing facility in Pithampur to expand business

6 step-down subsidiaries of Alembic Pharma dissolves

Ruchika Sharma9 Dec 2024 3:02 PM IST

Vadodara: Alembic Pharma has informed in a BSE filing that six step-down subsidiaries of the Company have been dissolved/ in the process of...

NGT seeks response from Environment Ministry on Hyderabad pharma unit blast

Ruchika Sharma9 Dec 2024 12:30 PM IST

New Delhi: The National Green Tribunal (NGT) has directed the Hyderabad regional office of the Union Ministry of Environment, Forest and Climate...

Biocon Biologics Yesafili gets Health Canada nod for eye diseases

Biocon gets EIR with VAI status from USFDA for Bengaluru API facility

Ruchika Sharma9 Dec 2024 11:30 AM IST

Bangalore: In a recent BSE filing, Biocon has informed that the U.S. Food and Drug Administration (US FDA) has issued an Establishment...

Novartis ianalumab Phase III trial meets primary endpoint in immune thrombocytopenia

US Appeals Court decision favors MSN Pharma in Novartis heart drug Entresto generic dispute

Ruchika Sharma9 Dec 2024 10:00 AM IST

Novartis suffered a legal setback on Wednesday as the company failed to persuade a U.S. appeals court to halt MSN Pharmaceuticals' proposed generic of...

Cohance Lifesciences announces USD 10 mn investment in cGMP Bioconjugation Suite at NJ Bio

Laurus Bio secures equity infusion of Rs 120 crore

Ruchika Sharma8 Dec 2024 1:30 PM IST

Hyderabad: Laurus Labs Ltd. has announced that its subsidiary, Laurus Bio, has signed a definitive agreement for an equity investment of Rs 120...

KKR divests 5.8 percent stake in JB Chemicals & Pharma for Rs 1460 crore

Teva to divest Teva-Takeda, its Business Venture in Japan

Ruchika Sharma8 Dec 2024 11:00 AM IST

Telaviv: Teva Pharmaceutical Industries Ltd. has announced that it has entered into an agreement with JKI, established by the fund managed and...

Bayer, Kumquat Biosciences ink pact to develop, commercialize KRAS G12D inhibitor

Gilead Sciences, Tubulis ink pact to develop ADC candidate for select solid tumor target

Ruchika Sharma8 Dec 2024 10:00 AM IST

Foster City: Gilead Sciences, Inc. and Tubulis have announced that they have entered into an exclusive option and license agreement to...

Novartis concludes acquisition of Regulus Therapeutics

Suven Pharma to acquire controlling stake in NJ Bio with investment of USD 64.4 million

Ruchika Sharma7 Dec 2024 4:29 PM IST

Mumbai: Suven Pharmaceuticals Limited has announced the acquisition of a controlling stake in NJ Bio Inc. with an investment of $64.4 million.Suven...

Carlyle to offload up to 10 percent stake in Piramal Pharma in Rs 26-27 billion deal: Report

Piramal Pharma to pay USD 407400 to resolve dispute with VetDC

Ruchika Sharma7 Dec 2024 3:28 PM IST

Mumbai: Through a recent BSE filing, Piramal Pharma has informed that it has agreed to pay USD 407,400 to US-based VetDC, Inc to settle a dispute over...

AstraZeneca Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

AstraZeneca Imfinzi granted priority review by USFDA for muscle-invasive bladder cancer

Ruchika Sharma7 Dec 2024 12:30 PM IST

Cambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok